Angiotensin III: a central regulator of vasopressin release and blood pressure.
Among the main bioactive peptides of the brain renin-angiotensin system, angiotensin (Ang) II and AngIII exhibit the same affinity for type 1 and type 2 AngII receptors. Both peptides, injected intracerebroventricularly, cause similar increases in vasopressin release and blood pressure. Because AngII is converted in vivo to AngIII, the identity of the true effector is unknown. This review summarizes new insights into the predominant role of brain AngIII in the control of vasopressin release and blood pressure and underlines the fact that brain aminopeptidase A, the enzyme forming central AngIII, could constitute a putative central therapeutic target for the treatment of hypertension.
Reaux
A
A
Institut National de la Santé et de la Recherche Médicale, Unité 36, Collège de France, Chaire de Médecine Expérimentale, 11 place Marcelin Berthelot, 75231 Paris Cedex 05, France.
Fournie-Zaluski
M C
MC
Llorens-Cortes
C
C
D000804:Angiotensin II / Q000008:administration & dosage / Q000502:physiology; D000805:Angiotensin III / Q000008:administration & dosage / Q000502:physiology*; D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism; D001794:Blood Pressure; D001921:Brain / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007276:Injections, Intraventricular; D014667:Vasopressins / Q000378:metabolism*
D014667:Vasopressins; D000804:Angiotensin II; D001127:Arginine Vasopressin; D000805:Angiotensin III